AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: An exploratory study
Yuan, Hai‐Yang, et al. Liver International (2024).
Categories: Publications
Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments
Chen, S., Zhou, J., Wu, X. et al. Hepatol Int (2024). https://doi.org/10.1007/s12072-024-10643-z
Potential of Using qFibrosis Analysis to Predict Recurrent and Survival Outcome of Patients with Hepatocellular Carcinoma after Hepatic Resection
Hsiao, Chih-Yang, et al. Oncology 1-11 (2024)
Leukotriene B4 receptor 1 (BLT1) does not mediate disease progression in a mouse model of liver fibrosis
Coyne, Erin., et al. Biochem J; 481 (3): 177–190.
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions
Ratziu, Vlad, et al. Journal of Hepatology. October 23, 2023 DOI:https://doi.org/10.1016/j.jhep.2023.10.015
Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection
Zhang, Mengyang and Chen, Shuyan, et al. Journal of Medical Virology 95.10 (2023): e29156.
Digital pathology for nonalcoholic steatohepatitis assessment
Arun J. Sanyal, Prakash Jha & David E. Kleiner. Nat Rev Gastroenterol Hepatol 21, 57–69 (2024).
Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models
Wang, Xiao-Xiao, et al. Frontiers in Medicine 10 (2023): 1172058.
Caloric Restriction Combined with Immobilization as Translational Model for Sarcopenia Expressing Key- Pathways of Human Pathology
de Jong, Jelle CBC, et al. Aging and Disease 14.3 (2023): 937.
Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study
Anstee, Quentin M., et al. Hepatology: 10-1097.